CPAT-01 is a standardised pharmaceutical product, derived from natural THC and CBD extracts and formulated into a liquid oral solution.
The phase 2A pilot study was a world-first, randomised, double-blind, placebo-controlled clinical trial.
AusCann has now received a full analysis of the trial’s clinical pain and lameness results, which indicate that CPAT-01 improved the pain, lameness and quality of life in the dogs.
The encouraging results of the study have given AusCann the confidence to continue moving forward with its development program.